Thymosin Beta-4
43-Amino Acid Regenerative Peptide | Tissue Repair & Healing
On this page
What is Thymosin Beta-4?
Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide the body already makes, studied by researchers for its role in tissue repair, wound healing, and cell regeneration. Research has looked at systemic effects following injection, including early human studies in wound healing, cardiac recovery after heart attack, and neurological recovery. It's supplied here strictly as a research chemical for laboratory study, not for human or animal treatment.
Key terms:
Thymosin Beta-4 is a thymosin peptide.
Thymosin Beta-4 (Tβ4) is a naturally occurring peptide of 43 amino acids. Researchers study it for tissue repair, wound healing, and cell regeneration. Reported mechanisms include angiogenesis (the growth of new blood vessels), reduced inflammation, and the movement and specialization of cells involved in healing.
Key research areas
- Studied for systemic regenerative effects
- Clinical trial data reported for several indications
- Systemic delivery studied for tissue-repair-related bioavailability
Researched dosing
This table reflects the dose ranges and routes used in published clinical-trial protocols for Thymosin Beta-4, presented as research-methodology reference, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Acute wound-healing models | 1.6 mg | Daily | Subcutaneous injection |
| Cardiac-protection models | 42 mg | Single dose within 6 hours of MI | IV bolus |
| Chronic tissue-repair models | 6 mg | Twice weekly | Subcutaneous injection |
| Neurological recovery models | 30 mg | Three times over 72 hours | IV infusion |
| General regeneration models | 2-5 mg | Daily or every other day | Subcutaneous injection |
| Standard study protocol | 0.6-14 mg | As per study design | SC or IV as indicated |
Commonly cycled 12 weeks on, 4+ weeks off.
How it works
At the cell level, Thymosin Beta-4 research looks at how the peptide appears to support blood-vessel formation, reduce inflammation, and help cells migrate to sites of tissue damage — the terms below name those biological processes.
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects.
Molecular data
These figures — molecular weight, 43-amino-acid sequence, chain length — are the chemistry ID researchers use to confirm a Thymosin Beta-4 sample's identity; at 43 residues, it's one of the longer peptides in this encyclopedia.
- Weight
- 4963.44 Da
- Length
- 43 amino acids
- Type
- Thymosin peptide
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
Research applications
This section lists the research areas — tissue repair, cardiovascular recovery, and neuroprotection — that scientists have studied for Thymosin Beta-4 in clinical trials; it's a summary of what's been investigated in the literature, not a claim about what it does for any individual person.
Tissue Repair
Clinical trials report 67% complete healing vs 25% with placebo in pressure ulcers. Studies also report increased tissue regeneration and reduced healing time in surgical wounds, and faster recovery in muscle, tendon, and ligament injury research.
Cardiovascular
A first-in-human study in heart attack patients reported potential benefits for repairing damaged tissue and cardiac function; the studied protocol used a 42mg single-dose IV bolus within 6 hours of MI.
Neuroprotection
Neurological-recovery research has used an IV infusion protocol (30mg three times over 72 hours) studied for neuroregenerative processes.
Dosage reference
- Doses used in research
- 2–6 mg
- Frequency in studies
- Once daily or every other day
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Initial: 24-48 hours; Tissue repair: 1-2 weeks; Full regeneration: 4-12 weeks
- Storage
- Lyophilized: room temperature; Reconstituted: 2-8°C for up to 14 days
- Cycle length
- Acute: 2-6 weeks; Chronic: 8-12 weeks with monitoring
- Break between cycles
- 2-4 weeks between treatment cycles for chronic conditions
Interactions
This list shows which other tissue-repair and recovery-focused peptides researchers study alongside Thymosin Beta-4, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried Thymosin Beta-4 powder into a research solution — the same basic water-based mixing process used for most peptide research.
- Allow lyophilized powder to reach room temperature before reconstitution
- Add bacteriostatic water slowly to the vial wall, avoiding direct contact with powder
- Gently swirl (do not shake vigorously) until completely dissolved
- Inspect solution for clarity - should be clear and colorless
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, use within As per manufacturer expiry
Reconstituted: 2-8°C, use within Up to 14 days
Open the Thymosin Beta-4 reconstitution calculatorQuality indicators
These are the checks researchers use to confirm a Thymosin Beta-4 sample is pure and correctly identified before it goes into a study — a quick reference against a Certificate of Analysis (COA), including confirming its published molecular weight.
Clear, colorless solution - Reconstituted Thymosin β4 should be clear and colorless without particles
Proper sterile packaging - Lyophilized powder in sterile vials with intact seals and labeling
Certificate of analysis - Third-party testing showing >98% purity and endotoxin levels <10 EU/mg
Appropriate molecular weight - HPLC/MS confirmation of 4,921 Da molecular weight for 43-amino acid sequence
Cloudy or discolored solution - Any turbidity or color change indicates degradation or contamination
Crystallization after reconstitution - Visible crystals suggest improper storage or expired product
Room temperature storage claims - Legitimate Thymosin β4 requires refrigeration after reconstitution
What to expect
This timeline summarizes what the clinical-trial literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Initial tissue response, possible mild injection site reactions
Accelerated healing becomes apparent, reduced inflammation
Significant tissue regeneration and functional improvement
Sustained benefits and near-complete healing in responsive conditions
Safety notes
This section covers handling cautions and regulatory notes for Thymosin Beta-4 in a laboratory setting — research-use-only scope, not medical advice for people.
- Monitor injection sites for local reactions or inflammation
- Use sterile technique to prevent infection at injection sites
- Start with lower doses to assess individual tolerance
- Discontinue if signs of allergic reaction or unusual side effects
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
First human study of Thymosin β4 in heart attack patients, demonstrating potential clinical benefits in repairing damaged tissue and improving cardiac function compared to control.
Randomized, double-masked, placebo-controlled study in 72 subjects showing significant positive effects on ocular discomfort and corneal staining in dry eye with excellent safety profile.
First-in-human randomized, placebo-controlled study establishing safety and pharmacokinetics of IV Thymosin β4 administration in healthy volunteers. Excellent safety profile, no dose-limiting toxicity.